Flexibility as Competitive Advantage
Executive SummaryMega-merged companies have to find twice as many drugs or drugs which are twice as valuable. But there are fewer such opportunities as managed care lifts higher innovation hurdles for manufacturers, particularly in developing the widely-used chroniccare medicines that form the basis of most drug companies' profit statements.
You may also be interested in...
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.